share_log

艾美疫苗:自願性公告 - 吸附破傷風疫苗提交臨床試驗預申請

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED

香港交易所 ·  Mar 3 19:00
Summary by Moomoo AI
艾美疫苗股份有限公司近日宣布,其吸附破傷風疫苗已提交臨床試驗預申請,此舉符合公司的產品研發戰略,並標誌著公司研發多聯多價產品的重要進展。該疫苗的開發旨在鞏固艾美疫苗在國內二類疫苗領域的行業地位,並促進其疫苗業務的可持續發展。此外,公司亦正在推進四聯疫苗的研發,預計於2024年開始提交相關臨床試驗申請。四聯疫苗旨在預防多種疾病,並可減少嬰幼兒接種針次,提高接種依從性。艾美疫苗董事會主席、執行董事兼首席執行官周延先生於2024年3月4日發布此消息。
艾美疫苗股份有限公司近日宣布,其吸附破傷風疫苗已提交臨床試驗預申請,此舉符合公司的產品研發戰略,並標誌著公司研發多聯多價產品的重要進展。該疫苗的開發旨在鞏固艾美疫苗在國內二類疫苗領域的行業地位,並促進其疫苗業務的可持續發展。此外,公司亦正在推進四聯疫苗的研發,預計於2024年開始提交相關臨床試驗申請。四聯疫苗旨在預防多種疾病,並可減少嬰幼兒接種針次,提高接種依從性。艾美疫苗董事會主席、執行董事兼首席執行官周延先生於2024年3月4日發布此消息。
EMERY VACCINES CO., LTD. RECENTLY ANNOUNCED THAT IT HAS SUBMITTED A CLINICAL TRIAL PRE-APPLICATION FOR ITS ASPIRATION VACCINE, IN LINE WITH THE COMPANY'S PRODUCT DEVELOPMENT STRATEGY AND MARKS AN IMPORTANT STEP FORWARD IN THE COMPANY'S DEVELOPMENT OF MULTI-VALUED PRODUCTS. The development of the vaccine aims to strengthen the industry position of EME in the domestic category 2 vaccine sector and to promote the sustainable development of its vaccine business. In addition, the company is advancing the development of a quadrivalent vaccine and is expected to start submitting applications for relevant clinical trials in 2024. The quadriplegic vaccine is designed to prevent a variety of diseases and can reduce infant and toddler vaccination rates and improve vaccination adherence. Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer of Amy Vaccines, issued this news on March 4, 2024.
EMERY VACCINES CO., LTD. RECENTLY ANNOUNCED THAT IT HAS SUBMITTED A CLINICAL TRIAL PRE-APPLICATION FOR ITS ASPIRATION VACCINE, IN LINE WITH THE COMPANY'S PRODUCT DEVELOPMENT STRATEGY AND MARKS AN IMPORTANT STEP FORWARD IN THE COMPANY'S DEVELOPMENT OF MULTI-VALUED PRODUCTS. The development of the vaccine aims to strengthen the industry position of EME in the domestic category 2 vaccine sector and to promote the sustainable development of its vaccine business. In addition, the company is advancing the development of a quadrivalent vaccine and is expected to start submitting applications for relevant clinical trials in 2024. The quadriplegic vaccine is designed to prevent a variety of diseases and can reduce infant and toddler vaccination rates and improve vaccination adherence. Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer of Amy Vaccines, issued this news on March 4, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more